ClinicalTrials.gg
Not yet recruitingNCT06772480Updated Jan 13, 2025

Thalidomide Versus Argon Plasma Coagulation in Gastric Antral Vascular Ectasia(GAVE)-Related Anaemia in Cirrhosis (TAG Trial)

An interventional study of Thalidomide and Argon Plasma Coagulation in Liver Cirrhosis and Gastric Antral Vascular Ectasia, sponsored by Institute of Liver and Biliary Sciences, India. Not yet recruiting at 1 site in India. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-01-13.

Sponsored by Institute of Liver and Biliary Sciences, India · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2026, 9 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 53 studies in Liver Cirrhosis by Institute of Liver and Biliary Sciences, India — 15 open to participants now, 15 under way, 1 of them phase 3. Liver Cirrhosis · Institute of Liver and Biliary Sciences, India.

Planned enrollment
17th of 42
100 · median 100
Started
2025
with 4 others
No phase
40 of 53
12 open now
Primary completion
2026-01
later than 9 of 14 live
Registered
47th of 53
by date

Among the 53 studies in Liver Cirrhosis by Institute of Liver and Biliary Sciences, India, this one is the 17th largest by planned enrollment of the 42 interventional ones that give a count, is one of 5 that started in 2025, is one of 40 with no phase, reaches primary completion later than 9 of the 14 other live ones, and was the 47th registered.

Liver Cirrhosis

1,302 studies on the registry are indexed under Liver Cirrhosis; 340 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

15 of the 53 studies in Liver Cirrhosis by Institute of Liver and Biliary Sciences, India are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Liver Cirrhosis by Institute of Liver and Biliary Sciences, India, or all of them as a file.
02

Study summary

Gastric Antral Vascular Ectasia (GAVE) is an erosive form of gastritis distinguished by veno-capillary ectasia, which manifests as tortuous columns of dilated vessels. Histologically, these vessels show dilated mucosal capillaries filled with fibrin thrombi, accompanied by fibromuscular hyperplasia and spindle cell proliferation of the lamina propria. GAVE is prevalent in about 12% of patients with cirrhosis, with 60-70% of these patients becoming transfusion-dependent due to severe anaemia caused by GAVE related bleeding. The most commonly used treatment for GAVE is endoscopic therapy using Argon Plasma Coagulation (APC), which, while effective, often requires multiple sessions due to a high recurrence rate of 30-60%. These frequent interventions increase the burden on patients and healthcare systems. As a result, alternative treatments have been sought. Thalidomide, known for its potent antiangiogenic properties, significantly lowers vascular endothelial growth factor (VEGF) levels, offering a promising non-invasive treatment option. Early studies, such as those by García-Pagán have demonstrated thalidomide's effectiveness in reducing transfusion requirements and managing bleeding in cirrhotic patients with GAVE, yet its comprehensive efficacy and safety profile remains under-studied. This project aims to rigorously evaluate the efficacy and safety of thalidomide compared to APC in managing GAVE-related anemia in cirrhotic patients. Through a controlled trial, this study will provide vital data to potentially shift treatment paradigms, enhance patient quality of life, and reduce the need for repetitive invasive procedures.

Read the detailed description

Aim: To evaluate and compare the efficacy and safety of thalidomide with argon plasma coagulation (APC) in managing gastric antral vascular ectasia (GAVE)-related anaemia in patients with cirrhosis.

Hypothesis: Thalidomide, due to its antiangiogenic effects, will more effectively reduce GAVE-related bleeding, improve haemoglobin levels, and decrease transfusion dependency compared to APC in patients with cirrhosis and GAVE-related anaemia.

Study Design:

Single-centre, open-label, randomised controlled trial to compare the efficacy and safety of thalidomide versus argon plasma coagulation (APC) in managing GAVE-related anaemia in cirrhotic patients.

Study Population:

Adult patients (aged 18-65 years) diagnosed with cirrhosis and endoscopically confirmed GAVE-related anaemia, presenting at the Institute of Liver and Biliary Sciences.

Randomization: Patients will be randomly assigned to receive either thalidomide or APC in a 1:1 ratio by block randomization method with block size of 10 and it will be implemented by using ILBS IWRS facility.

Follow-up and Assessments:

  • Patients will be followed every two weeks for the first month, then monthly up to six months. Assessments will include haemoglobin levels, the number of transfused blood units, the frequency of bleeding episodes, hospitalizations, and the number of required endoscopic sessions.
  • Adverse effects will be monitored and recorded at each visit.
03

Conditions studied

  • Liver Cirrhosis
  • Gastric Antral Vascular Ectasia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients (aged ≥18 - 65years)
  2. Cirrhosis
  3. Endoscopically confirmed diagnosis of GAVE

    1. +/- GAVE with active ooze
    2. Iron deficiency anemia*
  4. Ability to provide

Exclusion criteria

Exclusion Criteria:

  1. CTP >/=13
  2. Active GI Bleeding is caused by a cause other than GAVE.
  3. Renal insufficiency ( Creatinine >3mg/dL and/or on RRT)
  4. Pregnancy or childbearing age
  5. to thalidomide therapy: Severe peripheral neuropathy or seizures or a history of thromboembolic disease.
  6. Use of antiangiogenic drugs
  7. Bevacizumab, , octreotide
  8. Severe cardiopulmonary disorders
  9. H/o thalidomide use in the past 3months
  10. Contraindications to APC: Coagulopathy( Pacemaker or implantable defibrillator, \<45000, : >1.8 )
  11. Overt Hepatic Encephalopathy
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Thalidomide Group

    Patients will receive oral thalidomide starting at 50 mg daily, with a weekly increase of 50 mg up to a maximum of 200 mg daily, continued for four months.

    Drug: Thalidomide

  • Active comparator
    APC Group

    Patients will undergo APC treatment every 2-3 weeks initially, followed by maintenance sessions every three months as required.

    Procedure: Argon Plasma Coagulation

Interventions

  • Patients will receive oral thalidomide starting at 50 mg daily, with a weekly increase of 50 mg up to a maximum of 200 mg daily, continued for four months

  • ProcedureArgon Plasma Coagulation

    Patients will undergo APC treatment every 2-3 weeks initially, followed by maintenance sessions every three months as required.

06

What researchers measure

Primary outcomes

  1. Mean increase in hemoglobin levels from baseline

    Time frame: 4 months

Secondary outcomes

  1. Atleast 50 percent change in requirement of PRBCs transfusions at the end of 4 months

    Time frame: 4 months

  2. Increase in serum iron levels, percent transferrin saturation at the end of 4months

    Time frame: 4 months

  3. Change in amount of PRBC's transfused at the end of 4 months.

    Time frame: 4 months

  4. Change in GAVE related bleeding episodes at the end of 4 months

    Time frame: 4 months

  5. Number of hospitalizations due to GAVE related anemia, in 4 months

    Time frame: 4 months

  6. Duration of days of hospitalization due to GAVE related anemia in 4 months

    Time frame: 4 months

  7. Need of rescue endoscopic sessions in 4 months in thalidomide group

    Time frame: 4 months

  8. Endoscopic resolution of GAVE at the end of 4 months

    Endoscopic resolution is defined as endoscopic findings of GAVE as absent.

    Time frame: 4 months

  9. Change in VEGF levels in Thalidomide group at the end of 4 months

    Time frame: 4 months

  10. Change in pepsinogen levels in Thalidomide group at the end of 4 months

    Time frame: 4 months

  11. Change in gastrin levels in Thalidomide group at the end of 4 months

    Time frame: 4 months

  12. Adverse events in each group at the end of 4 months

    Time frame: 4 months

  13. Quality of life measures - Short Form 36

    Quality of life measures - Short Form 36 ranges from 0 to 100, 0 indicate maximum disability and 100 indicate no disability.

    Time frame: 4 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2025; primary completion for Jan 2026, 12 months later.

Of 207 non-industry interventional studies with no phase under Liver Cirrhosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 73. This study's planned 12 months is below that.

Counting every sponsor, half of 216 studies reached it within 32 months; a quarter within 17 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 1, 2025
First posted
Jan 13, 2025
StartEst.
Jan 5, 2025
Primary completionEst.
Jan 31, 2026
CompletionEst.
Jan 31, 2026
Last update
Jan 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06772480
Responsible party
Sponsor
First posted
Jan 13, 2025
Start date
Jan 5, 2025 (estimated)
Primary completion
Jan 31, 2026 (estimated)
Completion
Jan 31, 2026 (estimated)
Last update
Jan 13, 2025

Study contacts

Dr Aakula Suguna Sree, MD
Contact
sugunasreeaakula@gmail.com
01146300000
Dr Babu Lal Meena, DM
Contact
drbabupgi@gmail.com
01146300000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Thalidomide

Start the discussion